The role of long noncoding RNA (lncRNA) in adult hearts is unknown; also unclear is how lncRNA modulates nucleosome remodelling. An estimated 70% of mouse genes undergo antisense transcription 1 , including myosin heavy chain 7 (Myh7), which encodes molecular motor proteins for heart contraction 2 . Here we identify a cluster of lncRNA transcripts from Myh7 loci and demonstrate a new lncRNA-chromatin mechanism for heart failure. In mice, these transcripts, which we named myosin heavy-chain-associated RNA transcripts (Myheart, or Mhrt), are cardiac-specific and abundant in adult hearts. Pathological stress activates the Brg1-Hdac-Parp chromatin repressor complex 3 to inhibit Mhrt transcription in the heart. Such stress-induced Mhrt repression is essential for cardiomyopathy to develop: restoring Mhrt to the prestress level protects the heart from hypertrophy and failure. Mhrt antagonizes the function of Brg1, a chromatin-remodelling factor that is activated by stress to trigger aberrant gene expression and cardiac myopathy 3 . Mhrt prevents Brg1 from recognizing its genomic DNA targets, thus inhibiting chromatin targeting and gene regulation by Brg1. It does so by binding to the helicase domain of Brg1, a domain that is crucial for tethering Brg1 to chromatinized DNA targets. Brg1 helicase has dual nucleic-acid-binding specificities: it is capable of binding lncRNA (Mhrt) and chromatinized-but not naked-DNA. This dual-binding feature of helicase enables a competitive inhibition mechanism by which Mhrt sequesters Brg1 from its genomic DNA targets to prevent chromatin remodelling. A Mhrt-Brg1 feedback circuit is thus crucial for heart function. Human MHRT also originates from MYH7 loci and is repressed in various types of myopathic hearts, suggesting a conserved lncRNA mechanism in human cardiomyopathy. Our studies identify a cardioprotective lncRNA, define a new targeting mechanism for ATP-dependent chromatinremodelling factors, and establish a new paradigm for lncRNAchromatin interaction.
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By 59 and 39 rapid amplification of complementary DNA ends, we discovered an alternative splicing of Myh7 antisense transcription into a cluster of RNAs of 709 to 1,147 nucleotides (Mhrt RNAs), containing partial sequences of Myh7 introns and exons ( Fig. 1a and Supplementary Note). Mhrt RNAs were cardiac-specific (Fig. 1b) , present at low levels in fetal hearts, with increasing abundance as the hearts matured and Myh6/ Myh7 ratio increased (Fig. 1c) . RNA in situ analysis showed that Mhrt RNAs resided in the myocardium but not endocardium or epicardium ( Fig. 1d and Extended Data Fig. 1a) . Quantification of nuclear/cytoplasmic RNA in heart extracts revealed that Mhrt transcripts were primarily nuclear RNAs (Fig. 1e) . Coding substitution frequencies 4, 5 of Mhrt RNAs predicted a negative/low protein-coding potential, in vitro translation of Mhrt RNAs yielded no proteins, and ribosome profiling 6 revealed no/minimal ribosomes on Mhrt (Fig. 1f , Extended Data Fig. 1b-f and Supplementary Note). Consequently, Mhrt RNAs are non-coding RNAs in cardiomyocyte nuclei. Mhrt RNAs were downregulated by 46-68% in hearts pressureoverloaded by transaortic constriction (TAC) 3 , beginning by 2 days and lasting for $42 days after TAC (Fig. 2a) . Such Mhrt reduction coincided with the TAC-induced Myh6 to Myh7 isoform switch characteristic of cardiomyopathy [7] [8] [9] (Extended Data Fig. 2a ). To define Mhrt function, we focused on Mhrt779, the most abundant Mhrt species, with 779 nucleotides (Fig. 2b , c and Extended Data Fig. 2b -e). We generated a transgenic mouse line to restore Mhrt779 level in stressed hearts. This transgenic line, driven by tetracycline response element (Tre-Mhrt779), was crossed to a cardiac-specific driver line (Tnnt2-rtTA) 3 that employs troponin promoter (Tnnt2) to direct expression of reverse tetracycline-dependent transactivator (rtTA). The resulting Tnnt2-rtTA;Tre-Mhrt779 line (abbreviated as Tg779) enabled the use of doxycycline to induce Mhrt779 expression in cardiomyocytes. Within 7-14 days of doxycycline treatment, Mhrt779 increased by ,1.5-fold in left ventricles of Tg779 mice; this offset Mhrt779 suppression in TAC-stressed hearts to maintain Mhrt779 at the pre-stress level (Fig. 2d) . Six weeks after TAC, doxycycline-treated control mice (Tre-Mhrt779, Tnnt2-rtTA or wild type) developed severe cardiac hypertrophy and fibrosis with left ventricular dilatation and reduced fractional shortening. Conversely, doxycycline-treated Tg779 hearts-with Mhrt779 maintained at the pre-stress level-developed much less pathology, with a 45.7% reduction in the ventricle/body-weight ratio (Fig. 2e) and a 61.3% reduction in cardiomyocyte size ( Fig. 2f and Extended Data Fig. 3a) , minimal/absent cardiac fibrosis (Fig. 2g) , a 45.5% improvement of fractional shortening ( Fig. 2h and Extended Data Fig. 3b) , normalized left ventricular size (Fig. 2i) , and reduced pathological changes of Anf (also known as Nppa), Bnp (also known as Nppb), Serca2 (also known as Atp2a2), Tgfb1 and Opn (also known as Spp1) expression [10] [11] [12] [13] (Extended Data Figs 3c and 6e). To further test the cardioprotective effects of Mhrt, we induced Mhrt779 after 1-2 weeks of TAC when hypertrophy had begun. This approach reduced hypertrophy by 23% and improved fractional shortening by 33% in 8 weeks after TAC (Extended Data Fig. 3d-f ). The efficacy of late Mhrt779 introduction suggests that a sustained repression of Mhrt in stressed hearts is essential for continued decline of cardiac function.
To study Mhrt regulation, we examined the 59 upstream region of the Mhrt genomic site (22329 to 1143) (Extended Data Fig. 4a ) for signatures of a lncRNA promoter: RNA polymerase II (Pol II), histone H3 trimethylated lysine 4 (H3K4me3) and histone H3 trimethylated lysine 36 (H3K36me3) 4, 14, 15 . By chromatin immunoprecipitation (ChIP) of left ventricles, we found that this putative promoter contained four evolutionarily conserved elements (a1 to a4) 3 that were enriched with Pol II (a1 to a4), H3K4me3 (a1 and a4) and H3K36me3 (refs 14, 16-18) (a1 and a3/a4) (Extended Data Fig. 4a-d) . Conversely, no Pol II, H3K4me3 or H3K36me3 enrichment was found in control Shh and Vegfa promoters or in thymus and lungs that did not express Mhrt RNAs (Extended Data Fig. 4b-d) . These results reveal an active, cardiac-specific lncRNA promoter controlling Mhrt expression. We then asked how Mhrt was repressed in stressed hearts. We postulated that cardiac stress activated Brg1, leading it to occupy the a1-a4 promoter and to repress Myh6 (ref. 3) and Mhrt in opposite transcription directions (Extended Data Fig. 4a ). Indeed, Mhrt repression required Brg1: TAC suppressed Mhrt RNAs in control but not Brg1-null hearts (Tnnt2-rtTA;Tre-Cre;Brg1 fl/fl ) 3 (Extended Data Fig. 4e ). To test Brg1 activity on the Mhrt promoter, we cloned the a1-a4 promoter in the Mhrt transcription direction (22329 to 1143) into an episomal luciferase reporter, pREP4, that allows promoter chromatinization 19 . Brg1 was then transfected into Brg1-deficient SW13 cells 20 to reconstitute the Brg1/BAF complex for reporter assays. Brg1 transfection caused a ,50% reduction of Mhrt promoter activity (P , 0.0001), and such Mhrt repression was virtually abolished by Hdac inhibition with trichostatin-A or Parp inhibition 
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Adult heart Myocardium Epi. Myocardium E 1 1 E 1 5 E 1 8 P 2 P 4 P 6 P 9 P 3 1 P 4 0 P 6 0 P 1 2 0 Fig. 4f ), indicating a cooperative repressor function between Brg1, Hdac and Parp. ChIP verified that the Mhrt promoter (a1-a4) was occupied by Brg1, Hdac2/9 and Parp1 in stressed hearts 3 and in the pREP4 reporter episome (Extended Data Fig. 4g ). These findings indicate that Mhrt is repressed by the stressinduced Brg1-Hdac-Parp complex 3 through the a1-a4 promoter. Because Myh6 and Mhrt were both regulated by the a1-a4 promoter, we hypothesized that a1-a4 contained two elements to regulate Myh6 and Mhrt-with the a1 element controlling Myh6 and the a3/4 element controlling Mhrt (Extended Data Fig. 4a ). On a1 and a3/4 (but not a2), we found cardiac-specific enrichment of Brg1 (ref.
LETTER RESEARCH with PJ-34 (ref. 21) (Extended Data
3), H3K4me3 and H3K36me3 (Extended Data Fig. 4c-d) , and DNaseI genomic footprints ( Fig. 3a) 
22
. To test a3/4 for Mhrt regulation, we conducted deletional analysis of the a1-a4 promoter in the Mhrt transcription direction. In reporter assays, a3/4 was necessary and sufficient for Mhrt promoter activity and for Brg1-dependent Mhrt repression, whereas a1 was not essential for either (Extended Data Fig. 4h ). Conversely, a1 is necessary and sufficient for Brg1 to repress the Myh6 promoter 3 , but a3/4 is not required 3 . Therefore, a1 and a3/4 are two functionally distinct elements for Brg1 to separately control Myh6 and Mhrt.
In stressed hearts, Brg1 represses Myh6 and activates Myh7 (ref.
3), causing a pathological switch of Myh6/7 expression, contributing to cardiomyopathy 23 . This stress/Brg1-dependent Myh switch was largely eliminated by Mhrt779 (Fig. 3b) , and the inhibition of the Myh switch by Mhrt did not involve RNA-RNA sequence interference between Mhrt and Myh (Extended Data Fig. 5a -j and Supplementary Note). Instead, it required a physical interaction between Mhrt RNA and Brg1. RNA immunoprecipitation of TAC-stressed adult hearts or Brg1-expressing neonatal hearts showed that Brg1 co-immunoprecipitated with Mhrt779 but not control RNAs, and that Mhrt779 complexed with Brg1 but not with the polycomb proteins Ezh2 or Suz12 ( Fig. 3c and Supplementary Note). These results suggest that Mhrt binds to Brg1 to influence its gene regulation.
We then tested how Mhrt regulated Brg1 activity on its in vivo target genes, including Myh6 (ref. (Fig. 3d) , causing a 56-76% loss of Brg1-controlled Myh switch and Opn activation ( Fig. 3b and Extended Data Figs 6e, 7g). We then used primary rat ventricular cardiomyocytes to conduct reporter assays. In these cells, as observed in vivo, Brg1 repressed Myh6 and activated Myh7 and Opn promoters; Mhrt779 reduced Brg1 activity on these promoters by 54-80% (Fig. 3e) . Accordingly, Mhrt prevents Brg1 from binding to its genomic targets to control gene expression.
How Brg1 or ATP-dependent chromatin remodellers recognize their target promoters is an important but not fully understood issue in chromatin biology. Biochemically, recombinant Brg1 proteins and in vitro transcribed Mhrt779 could directly co-immunoprecipitate without involving other factors (Fig. 3f ). An electrical mobility shift assay (EMSA) showed that Brg1 shifted biotin-labelled Mhrt779 to form a low mobility 
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protein-RNA complex that was competitively disrupted by unlabelled Mhrt779 (Fig. 3f) . Brg1, which belongs to the SWI/SNF family of chromatin-remodelling factors, contains a helicase/ATPase core that is split by an insertion into two RecA-like domains: DEAD-like helicase superfamily C-terminal domain, D1 (DExx-c) and helicase superfamily C-terminal domain, D2 (HELIC-c) 24, 25 , with signature motifs of DEADbox, superfamily 2 RNA helicase 25, 26 ( Fig. 3g and Extended Data Fig. 8 ). SWI/SNF proteins although conserved with RNA helicases, were observed to bind DNA 27 and mediate DNA structural changes and repair 19 . The binding properties of Brg1 remained undefined. To test whether Mhrt could bind to Brg1 helicase, we generated maltose-binding protein (MBP)-tagged recombinant proteins that contained the Brg1 DExx-c domain (MBP-D1, amino acids 774-913), the HELIC-c domain with C-terminus extension (MBP-D2, 1086-1310), or the entire helicase (MBP-D1D2, 774-1310) (Extended Data Fig. 9a ). D1D2 showed the highest Mhrt binding affinity (dissociation constant (K d ) 5 0.76 mM); D1 showed moderate affinity (K d 5 1.8 mM); D2 modest affinity (K d . 150 mM); and MBP did not bind at all (Fig. 3h, i) . Therefore, Brg1 helicase binds Mhrt with high affinity.
Contrary to its potent RNA binding, Brg1 helicase showed no detectable binding to the naked DNA of the Myh6 promoter (596 bp, 2426 to 1170, critical for the control of Myh6 by Brg1 (ref.
3)) (Extended Data  Fig. 9b ). To test whether Brg1 helicase could bind chromatinized DNA, we generated nucleosomal DNA in vitro by assembling histone octamers (histones H2A, H2B, H3 and H4) 28 on Myh6 promoter DNA, as well as on control neomycin phosphotransferase gene (Neo) and 5S ribosomal (r)DNA (5S rDNA). We achieved 50-65% efficiency of nucleosome assembly, comparable between Myh6, Neo and 5S rDNA (Fig. 4a) . Because the large nucleosome size precluded a clear EMSA resolution, we used amylose to pull down MBP-tagged D1D2 proteins. We found that D1D2 pulled down nucleosomal Myh6 promoter DNA but not the naked one (Fig. 4b) . The pull-down efficiency of nucleosomal Myh6 was ,3-6-fold that of Neo or 5S rDNA (Fig. 4c) , and Mhrt779 was capable of disrupting D1D2-Myh6 pull-down (Fig. 4d) . Although D1D2 bound to histone H3 (Fig. 4e) , histone binding was insufficient to anchor D1D2 to nucleosomal DNA, as D1D2 bound poorly to nucleosomal Neo and 5S rDNA that also contained histones (Fig. 4c) . Therefore, chromatinized DNA targets are biochemically recognized by Brg1 helicase, and this process is inhibited by Mhrt.
To test the ability of Brg1 to distinguish chromatinized from naked DNA promoters in cells, we cloned Myh6 promoter into the luciferase reporter plasmid pREP4 (allowing promoter chromatinization 19 ) and pGL3 (containing naked, non-chromatinized promoter). In rat ventricular cardiomyocytes and SW13 cells, ChIP and luciferase analyses showed that Brg1 bound and repressed chromatinized but not naked Myh6 promoter (Fig. 4f, g and Extended Data Fig. 9c, d ). However, without D1/D2 domain or in the presence of Mhrt, Brg1 was unable to bind or repress chromatinized Myh6 promoter (Fig. 4h-j and Extended Data Fig. 9e) , indicating the necessity of D1D2 for the interaction between Brg1, chromatin and Mhrt. Consistently, all our genetic, biochemical and cellular MHRT originates from MYH7 and is transcribed into MYH7. MYH7 exons and introns are indicated. R1 and R2 are strand-specific primers; F1 and R1 target MHRT and MYH7; F2 and R2 are specific for MHRT. l, Quantification of MHRT in human heart tissues. Ctrl, control; ICM, ischaemic cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; LVH, left ventricular hypertrophy. m, Working model of a Brg1-Mhrt feedback circuit in the heart. Brg1 represses Mhrt transcription, whereas Mhrt prevents Brg1 from recognizing its chromatin targets. Brg1 functions through two distinct promoter elements to bidirectionally repress Myh6 and Mhrt expression. n, Molecular model of how Brg1 binds to its genomic DNA targets. Brg1 helicase (D1D2) binds chromatinized DNA, C-terminal extension (CTE) binds histone H3, and bromodomain binds acetylated histone H3 or H4. P values: Student's t-test. Error bars show s.e.m.
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studies show that Brg1 requires the helicase domain to bind to chromatinized DNA targets, and Mhrt seizes the helicase to disrupt Brg1-chromatin binding.
We then asked how Brg1 surpassed its basal suppression by Mhrt to control Myh, Mhrt, Opn, or other genes to trigger cardiomyopathy (Supplementary Note). Amylose pull-down experiments showed that Brg1 dose-dependently escaped from Mhrt inhibition to occupy Mhrt promoter (Extended Data Fig. 10 ). Brg1 protein, which increases under stress conditions 3 , could therefore outrun Mhrt and gain control over the Mhrt promoter to repress Mhrt expression and tip the balance towards Brg1. Contrary to the endogenous Mhrt that was repressible by Brg1, the Mhrt transgene (Tg779)-driven by Tnnt2/Tre promoters-was not subject to repression by Brg1 and was thus able to keep Mhrt at pre-stress levels to inhibit Brg1 and reduce hypertrophy. This further demonstrates the necessity of Mhrt repression for myopathy to develop.
Human MYH7 loci encoded RNA that resembled Mhrt in primary sequence and secondary structure, as predicted by minimal free energy 29 ( Fig. 4k and Extended Data Fig. 11a, b) . Human MHRT was also repressed in stressed hearts, with 82.8%, 72.8% and 65.9% reduction of MHRT in hypertrophic, ischaemic or idiopathic cardiomyopathy tissues, respectively ( Fig. 4l and Extended Data Fig. 11c ). This suggests a conserved MHRT mechanism of human cardiomyopathy.
Mhrt is the first example, to our knowledge, of a lncRNA that inhibits myopathy and chromatin remodellers. Reciprocal Mhrt-Brg1 inhibition constitutes a feedback circuit critical for maintaining cardiac function (Fig. 4m) . The helicase core of Brg1, combined with the histone-binding domains of the Brg1/BAF complex, adds a new layer of specificity control to Brg1/BAF targeting and chromatin remodelling (Fig. 4n) . The Mhrt-helicase interaction also exemplifies a new mechanism by which lncRNA controls chromatin structure. To further elucidate chromatin regulation, it will be essential to define helicase domain function in all ATPdependent chromatin-remodelling factors and to identify new members of lncRNA that act through this domain to control chromatin. The cardioprotective Mhrt may have translational value, given that RNA can be chemically modified and delivered as a therapeutic drug. This aspect of lncRNA-chromatin regulation may also inspire new therapies for human disease.
METHODS SUMMARY
Tg779 mouse generation, rapid amplification of cDNA ends (RACE), RNA in situ hybridization, RT-qPCR, codon substitution frequencies (CSF), echocardiography, northern blot, EMSA, ChIP, RNA immunoprecipitation, reporter assay, nucleosome assembly, and the amylose pull-down assay were performed as described 3, 4, 28 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
Mice, animal sample size, and randomization. For the generation of Tg779 mice, Mhrt779 was cloned into the pTRE2 backbone (Clonetech). A DNA fragment containing the Tre promoter and Mhrt779 were injected into the pronucleus of fertilized oocytes (B6C3H/F1). Embryos were implanted into a pseudopregnant CD-1 mouse. The Tre-Mhrt779 transgene was identified by PCR genotyping using primers CGCCTGGAGACGCCATCCAC and TGTCTTCAAAGCTGACTCCCT. Tre-Mhrt779 mice with ,3 copies of the transgene were backcrossed with Tnnt2-rtTA mice as described previously 3, 30 to generate Tnnt2-rtTA;Tre-Mhrt779 (Tg779) mice. The number of animals used (n) is denoted in each test in the figures, including technical replicates when applicable. We routinely used mouse littermates to control and perform our experiments. Each subgroup of experiments had n 5 3 to 14 biological replicates, many of which had technical replicates of three. Assignment to each experimental subgroup was based on genotypes. Littermate mice with the same genotypes regardless of gender were randomly selected from the cage and assigned to different control and experimental subgroups. Major procedures were blinded. The use of mice for studies was in compliance with the regulations of Indiana University, Stanford University and the National Institutes of Health. RACE and cloning of full length of Mhrt transcripts. The 39 and 59 RACE were performed using the FirstChoice RLM-RACE Kit (Ambion) following the manufacturer's instruction. RNA was extracted from adult heart ventricles. Primers used for 39 and 59 RACE were designed based on the known sequence information: TC ATTGGCACGGACAGCATC (first-round Mhrt 39-prime specific) and GAGCA TTTGGGGATGGTATAC (second-round Mhrt 39-prime specific); CAACACTT TTCATTTTCCTCTTT (first-round Mhrt 59-prime specific) and TCTGCTTCA TTGCCTCTGTTT (second-round Mhrt 59-prime specific). Once we reached the 59 and 39 cDNA ends, we used primers F1 ( Fig. 1a ; AAGAGCCCTACAGTCTG ATGAACA) and R1 ( Fig. 1a; CCTTCACACAAACATTTTATTT) to amplify the full-length Mhrt transcripts and cloned them into pDrive TA cloning vector (Qiagen) for sequencing. Mhrt RNAs were also further cloned into shuttle vector pAdd2 (refs 31, 32) for expression in cells. Northern blot and in situ hybridization. We obtained 5 mg of total RNA using Quick-RNA Mini Kit (Zymo Research). RNA blot was performed using NorthernMax Kit (Ambion) following the manufacturer's protocol. Single-stranded RNA probe was generated by in vitro transcription with MaxIscript SP6/T7 kit (Ambion) with ATP [a- 32 P] (PerkinElmer) using full-length Mhrt779, Myh6 and Myh7 as the template and followed by digestion with DNase I (Ambion). Hybridization was performed at 65 uC. The blot was washed and imaged by Phosphor storage scanning by Typhoon 8600 Imager (GE Healthcare). In situ hybridization experiments were performed as previously described 3, 33 . RNA fractionation. To isolate cytosolic and nuclear RNAs from adult heart tissues, we used a PARIS kit (Ambion) and followed the manufacturer's instruction. Ten milligrams of tissue were homogenized in cell fractionation buffer thoroughly before centrifuging for 5 min at 500g. Supernatant was collected as the cytosolic fraction, while the nuclear pellet was washed and lysed by cell disruption buffer. Such samples were further mixed with 23 lysis/binding solution before extracting RNA using the manufacturer's protocol. Codon substitution frequency predication. To measure the coding potential of Mhrt, we used the previously described codon substitution frequencies (CSF) method 4, 5 to evaluate the evolutionary characteristics in their alignments with orthologous regions in six other sequenced mammalian genomes (rat, human, hamster, rhesus monkey, cat and dog). CSF generates a likelihood score for a given sequence considering all codon substitutions observed within its alignment across multiple species, which was based on the relative frequency of similar substitutions occurring in known coding and noncoding regions. CSF compares two empirical codon models; one generated from alignments of known coding regions and the other according to noncoding regions, producing a likelihood ratio. The ratio reflects whether the protein-coding model better explains the alignment. Ribosome profiling and RNA deep sequencing. For ribosome profiling 6 , overexpression of the predominant species of Mhrt (Mhrt779) along with HOTAIR were achieved through co-transfecting pAdd2-779 and pAdd2-HOTAIR into SW13 cells. The cells were then lysed to extract ribosome-associated RNA fragments using ARTseq Ribosome Profiling Kit (Epicentre, Illumina). The RNA fragments were further converted into a DNA library through end repair, adaptor ligation, reverse transcription circularization, and PCR amplification. A conventional RNA-seq library was also prepared, with total RNA extracted from those cells with an miRNeasy Mini Kit (Qiagen #217004). The libraries were further processed according to an MiSeq Sample Prep sheet, and an MiSeq 50 cycle kit was used for sequencing. PCR products (1.25 pmol) were used for sequencing. Approximately 600,000-700,000 reads were properly paired and used for further analysis. The resulting reads were aligned to the human hg19 or mouse mm10 genome using Bowtie2 v.2.0.0.6 (ref. 34 ). Mapped reads were visualized on the UCSC browser as bigwig files generated using samtools v.0. 1.18 (ref. 35), bedtools v.2.16.1 (ref. 36) , bedClip and bedGraphToBigWig.
For quantification of fragments per kilobase of exon per million fragments mapped (FPKM) values, cuffdiff as part of the tophat suite v.2.0.8b 37 was run on a merged bam file containing the human and the Mhrt reads using a custom gtf file comprising the human hg19 iGenome and the Mhrt transcripts. To generate scatter plots of the genes, cuffdiff files were used for visualization with cummerbund v.2.3.1 (ref. 37) . In vitro translation and biotin labelling. TNT Quick Coupled Transcription/ Translation System (Promega) was used for in vitro translation. Briefly, 1 mg plasmids of control (luciferase) and various Mhrt species inserted into pDrive vector were added to 40 ml rabbit reticulocyte lysates containing 35 S-methionine. After 1 h of incubation, the reactions were analysed on 10-20% Tris-Tricine gel. The gel was dried and visualized by the Typhoon 8600 Imager (GE Healthcare). Biotin-NTP was added to the in vitro translation reaction. Total RNAs were extracted and the biotin-labelled RNAs were detected subsequently by IRDye 680 Streptavidin (Li-COR, 926-68079) using an Odyssey Infrared Imaging System. TAC. The TAC surgery was performed as described 3 on adult mice of 8-10 weeks of age and between 20 and 25 g in weight. Mice were fed with doxycycline food pellets (6 mg doxycycline per kg of food; Bioserv) 7-14 days before the TAC operation. Mice were anaesthetized with isoflurane (2-3%, inhalation) in an induction chamber and then intubated with a 20-gauge intravenous catheter and ventilated with a mouse ventilator (Minivent, Harvard Apparatus). Anaesthesia was maintained with inhaled isoflurane (1-2%). A longitudinal 5 mm incision of the skin was made with scissors at the midline of sternum. The chest cavity was opened by a small incision at the level of the second intercostal space 2-3 mm from the left sternal border. While opening the chest wall, the chest retractor was gently inserted to spread the wound 4-5 mm in width. The transverse portion of the aorta was bluntly dissected with a curved forceps. Then, 6-0 silk was brought underneath the transverse aorta between the left common carotid artery and the brachiocephalic trunk. One 27-gauge needle was placed directly above and parallel to the aorta. The loop was then tied around the aorta and needle, and secured with a second knot. The needle was immediately removed to create a lumen with a fixed stenotic diameter. The chest cavity was closed by 6-0 silk suture. Shamoperated mice underwent similar surgical procedures, including isolation of the aorta and looping of the aorta, but without tying of the suture. The pressure load caused by TAC was verified by the pressure gradient across the aortic constriction measured by echocardiography. Only mice with a pressure gradient .30 mm Hg were analysed for cardiac hypertrophy, echocardiography and other purposes. Echocardiography. The echocardiographer was blinded to the genotypes and surgical procedure. Transthoracic ultrasonography was performed with a GE Vivid 7 ultrasound platform (GE Health Care) and a 13 MHz transducer was used to measure aortic pressure gradient and left ventricular function. Echocardiography was performed on control and Tnnt2-rtTA;Tre-Mhrt779 (Tg779) mice at designated time points after the TAC procedure. To minimize the confounding influence of different heart rates on the aortic pressure gradient and left ventricular function, the flow of isoflurane (inhalational) was adjusted to anaesthetize the mice while maintaining their heart rates at 450-550 beats per minute. The peak aortic pressure gradient was measured by continuous-wave Doppler across the aortic constriction. Left ventricular function was assessed by M-mode scanning of the left ventricular chamber, standardized by two-dimensional, short-axis views of the left ventricle at the mid papillary muscle level. Left ventricular chamber size and wall thickness were measured in at least three beats from each projection and averaged. Left ventricular internal dimensions at diastole and systole (LVIDd and LVIDs, respectively) were measured. The fractional shortening (FS) of the left ventricle was defined as 100% 3 (1 2 LVIDs/LVIDd), representing the relative change of left ventricular diameters during the cardiac cycle. The mean FS of the left ventricle was determined by the average of FS measurements of the left ventricular contraction over five beats. P values were calculated by Student's t-test. Error bars indicate s.e.m. Histology, trichrome staining and morphometric analysis of cardiomyocytes. Histology and trichrome staining were performed as described 38, 39 . Trichrome stain (Masson) kit (Sigma) was used and the manufacturer's protocol was followed. For morphometric analysis of cardiomyocytes, paraffin sections of the heart were immunostained with a fluoresecin isothiocyanate-conjugated wheat germ agglutinin (WGA) antibody (F49, Biomeda) that highlighted the cell membrane of cardiomyocytes. Cellular areas outlined by WGA were determined by the number of pixels enclosed using ImageJ software (NCBI). Approximately 250 cardiomyocytes of the papillary muscle at the mid-left ventricular cavity were measured to determine the size distribution. P values were calculated by Student's t-test. Error bars indicate s.e.m. RT-qPCR and strand-specific reverse transcription PCR analysis. RT-qPCR analyses were performed as described 3, 38 . The following primer sequences (listed later) were used. RT-qPCR reactions were performed using SYBR green master mix (BioRad) with an Eppendorf realplex, and the primer sets were tested to be quantitative. Threshold cycles and melting curve measurements were performed with software. P values were calculated by Student's t-test. Error bars indicate s.e.m. To conduct strand-specific RT-PCR analysis, human total RNA and Superscript III First-Strand PCR primers for ChIP-qPCR are as follows. Mouse ChIP-Myh6 promoter-F, GCAGATAGCCAGGGTTGAAA, mouse ChIP-Myh6 promoter-R, TGGGTAA GGGTCACCTTCTC; mouse ChIP-Myh7 promoter-F, GTGACAACAGCCCT TTCTAAAT, mouse ChIP-Myh7 promoter-R, CTCCAGCTCCCACTCCTACC; mouse ChIP-Shh promoter-F, GAGAACATTACAGGGTAGGAA, mouse ChIPShh promoter-R, GAAGCAGTGAGGTTGGTGG; mouse ChIP-Vegfa promoter-F, CAAATCCCAGAGCACAGACTC, mouse ChIP-Vegfa promoter-R, AGCGCAG AGGCTTGGGGCAGC; human ChIP-GAPDH promoter-F, TACTAGCGGTTTT ACGGGCG, human ChIP-GAPDH promoter-R, TCGAACAGGAGGAGCAGAG AGCGA. RNA immunoprecipitation. RNA immunoprecipitation (RNA-IP, RIP) was conducted as described 4 with some modifications. Briefly, P1 hearts, sham hearts or those from mice that had undergone TAC, or SW13 cells were crosslinked and lysed with lysis buffer (10 mM HEPES pH 7.5, 85 mM KCl, 0.5% NP-40, 1 mM dithiothreitol (DTT), 13 protease inhibitor) for tissues or lysis buffer (10 mM Tris-HCl pH 8.1, 10 mM NaCl, 1.5 mM MgCl 2, 0.5% NP-40, 1 mM DTT, 13 protease inhibitor) for cells. Nuclei were isolated and sonicated using Bioruptor (Diagenode) (30 s on, 30 s off, power setting H, 5 min, performed twice) in nuclear lysis buffer (50 mM Tris-HCl pH 8.1, 150 mM NaCl, 0.1% NP-40, 1 mM DTT, protease inhibitor, ribonuclease inhibitor). The nuclear extract was collected and incubated with primary antibodies at 4 uC overnight together with Manga ChIP Protein G Magnetic Beads (Millipore). The beads were washed by wash buffer I (20 mM Tris-Hcl pH 8.1, 150 mM NaCl, 1% Triton X-100 and 0.1% SDS) three times, and wash buffer II (20 mM Tris-Hcl pH 8.1, 500 mM NaCl, 1% Triton X-100 and 0.1% SDS) three times. Beads were then resuspended in 150 ml 150 mM RIPA (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate) with 5 ml Proteinase K and incubated for 1 h at 65 uC. We added 1 ml of TRIzol to the sample, and RNA was extracted using the Quick-RNA Mini Kit with the on-column DNase I digest (ZymoResearch). RT and qPCR were then conducted with the purified RNA. The antibodies used for the immunoprecipitation are anti-BRG1 J1 antibody Reporter assay and truncation of the Mhrt promoter. For the Mhrt promoter reporter assay, plasmid was constructed by inserting ,2.5 kb mouse Mhrt promoter into the episomal pREP4-Luc plasmid 3, 19, 38, 43 through cloning the PCRamplified region of the promoter by using primers ACCGGCCTGAACCCCACT TCC and ATGTCGAGACAGGGAACAGAA. Mouse Myh6 (2426 to 1170, based on new genome annotation) and Myh7 (23561 to 1222) reporter constructs were described previously 3 . These vectors were transfected into rat neonatal cardiomyocytes or SW13 cells using lipofectamine 2000 (Invitrogen) along with plasmids expressing mouse Brg1 (actin-mBrg1-IRES-eGFP) or a matching empty vector plasmid (gifts from G. Crabtree) as well as an episomal Renilla luciferase plasmid (pREP7-RL) to normalize transfection efficiency. The transfected cells were cultured for 48 h and harvested for luciferase assay using the dual luciferase assay kit (Promega). For naked DNA reporter, mouse Myh6 promoter (2426 to 1170) was inserted in pGL3 vector (Promega), and Renilla luciferase plasmid phRL-SV40 (gifts from J. Chen) was used as a normalizer. Dual luciferase assay was performed according to the manufacturer's instruction 48 h after transfection. For deletional analysis of the Mhrt promoter, various regions of the promoter were deleted from the full-length pREP4-Mhrt. The constructs were further analysed by transfecting into SW13 cells. RNA-EMSA and K d calculation. Biotin-labelled RNA probe was generated by in vitro transcription with MAXIscript SP6/T7 kit (Ambion) with biotin labelling NTP mixture (Roche) using linearized pDrive-Mhrt779 construct as the template and followed by digestion with DNase I (Ambion). EMSA was performed by using the LightShift Chemiluminescent RNA EMSA Kit (Thermo Scientific). The labelled probe was incubated with appropriate amounts of recombinant proteins in 10 ml in the 13 binding buffer (10 mM HEPES-KOH, pH 7.3, 10 mM NaCl, 1 mM MgCl 2 , 1 mM DTT) with 5 mg tRNA carrier at room temperature for 30 min. The reactions were then loaded onto 1% 0.53 TBE agarose gel and transferred to BrightStarPlus positive charged membrane. The biotin-labelled probes were detected and quantified subsequently by IRDye 680 Streptavidin (Li-COR, 926-32231) using Odyssey Infrared Imaging System. The shifted signals were quantified and plotted against amount of the MBP, MBP-D1, MBP-D2 and MBP-D1D2 proteins using a previously described method 26 with GraphPad Prism (GraphPad). The software facilitates the fitting of nonlinear regression model and calculation of K d values based on the fitting curve. The errors and r 2 values were also generated from the fitting curve. Protein expression and purification of Brg1 helicase domains. To generate MBP fusion proteins of mouse Brg1 helicase domains, the DExx-box domain (D1) (amino acids 7742913 of Brg1), helicase-C domain (D2) together with C-terminal extension (CTE) (amino acids 108621310 of Brg1), as well as the entire helicase region (D1D2) (77421310) were amplified by PCR and cloned into pMAL vector. MBP fusion proteins were induced by isopropyl-b-D-thiogalactoside (IPTG) and purified by amylose resin (E8021S, NEB). Nucleosome assembly and amylose pull-down. Nucleosome assembly was performed by using EpiMark Nucleosome Assembly Kit (E5350S, NEB) following the manufacturer's instruction 28 . In brief, recombinant human core histone octamer, which consists of the 2:1 mix of histone H2A/H2B dimer and histone H3.1/H4 tetramer, were mixed with purified 5S rDNA (208 bp; N1202S, NEB), Neo (512 bp, amplified from pST18-Neo; 1175025, Roche), Myh6 core promoter (596 bp, 2426 to 1170) and Mhrt core promoter (a3/a4, 596 bp, 22290 to 21775) DNA at 2 M NaCl. PCR primers to amplify Neo are CGATGCGCTGCGAATCGGGA and CACTGA AGCGGGAAGGGACT. The salt concentration was gradually lowered by dilution to allow the formation of nucleosomes. The EMSA assay was used to assess the efficiency of nucleosome assembly. For amylose pull-down assay, the amylose resin (E8021S, NEB) was washed thoroughly and equilibrated with binding buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl) before incubation with purified MBP or MBP-D1D2 proteins for 2 h. Nucleosome mixture or naked DNA mixture of 5S rDNA, Neo and Myh6 promoter DNA were added for incubation at 4 uC for overnight. The resin was then washed excessively by washing buffer (20 mM Tris-HCl, pH 8.1, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS) before decrosslinking and extraction of the DNA with phenol:chloroform:isoamyl alcohol. For competition assays, in vitro transcribed Mhrt779 was incubated with MBP-D1D2 in binding buffer (10 mM HEPES-KOH, pH 7.3, 10 mM NaCl, 1 mM MgCl 2 , 1 mM DTT) with ribonuclease inhibitor at room temperature for 30 min before adding nucleosomal DNA. The subsequent incubation, wash and DNA purification were performed as regular amylose pull-down assays. The qPCR signal of individual pulldown reaction was standardized to its own input RT-qPCR signal. qPCR primers were designed to amplify the 5S rDNA (CAAGCAAGAGCCTACGACCA; ATTC GTTGGAATTCCTCGGG), Neo (TAAAGCACGAGGAAGCGGTC; TCGACCC CAAGCGAAACAT), Myh6 promoter (GCAGATAGCCAGGGTTGAAA; TGGG TAAGGGTCACCTTCTC) and Mhrt promoter (ATGCCAAATGGTTGCTCTTT; GAGCTTGAGAACCAGGCAGT).
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